Spero Therapeutics Analyst Ratings
Spero Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 508.7% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 09/05/2023 | 508.7% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 08/14/2023 | 508.7% | HC Wainwright & Co. | $6 → $7 | Maintains | Buy |
| 08/01/2023 | 421.74% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/20/2023 | 421.74% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/10/2023 | 421.74% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 09/26/2022 | 421.74% | HC Wainwright & Co. | $7 → $6 | Maintains | Buy |
| 09/23/2022 | 595.65% | Evercore ISI Group | $2 → $8 | Upgrades | In-Line → Outperform |
| 08/15/2022 | 508.7% | HC Wainwright & Co. | $10 → $7 | Maintains | Buy |
| 05/23/2022 | 769.57% | HC Wainwright & Co. | $37 → $10 | Maintains | Buy |
| 05/20/2022 | 73.91% | Berenberg | → $2 | Downgrades | Buy → Hold |
| 05/17/2022 | 334.78% | Cantor Fitzgerald | $27 → $5 | Maintains | Overweight |
| 05/04/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 05/04/2022 | 73.91% | Evercore ISI Group | $40 → $2 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 3117.39% | HC Wainwright & Co. | $43 → $37 | Maintains | Buy |
| 03/21/2022 | 3639.13% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 10/01/2021 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 01/22/2021 | 3378.26% | HC Wainwright & Co. | $33 → $40 | Maintains | Buy |
| 12/16/2020 | 3986.96% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 11/23/2020 | 2769.57% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 09/29/2020 | 5986.96% | Evercore ISI Group | → $70 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 2334.78% | HC Wainwright & Co. | $25 → $28 | Reiterates | → Buy |
| 03/17/2020 | 1726.09% | Stifel | $22 → $21 | Maintains | Buy |
| 11/05/2019 | 2943.48% | HC Wainwright & Co. | $28 → $35 | Maintains | Buy |
| 09/09/2019 | — | Janney Montgomery Scott | Initiates Coverage On | → Buy | |
| 09/04/2019 | 2334.78% | HC Wainwright & Co. | → $28 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/14/2023 | 508.7% | HC Wainwright & Co. | → 7 美元 | 重申 | 购买 → 购买 |
| 09/05/2023 | 508.7% | HC Wainwright & Co. | → 7 美元 | 重申 | 购买 → 购买 |
| 08/14/2023 | 508.7% | HC Wainwright & Co. | 6 美元 → 7 美元 | 维护 | 买 |
| 08/01/2023 | 421.74% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 07/20/2023 | 421.74% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
| 2023 年 10 月 4 日 | 421.74% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
| 09/26/2022 | 421.74% | HC Wainwright & Co. | 7 美元 → 6 美元 | 维护 | 买 |
| 09/23/2022 | 595.65% | Evercore ISI 集团 | $2 → 8 美元 | 升级 | 盘中 → 跑赢大盘 |
| 08/15/2022 | 508.7% | HC Wainwright & Co. | 10 美元 → 7 美元 | 维护 | 买 |
| 05/23/2022 | 769.57% | HC Wainwright & Co. | 37 美元 → 10 美元 | 维护 | 买 |
| 05/20/2022 | 73.91% | 贝伦贝格 | → 2 美元 | 降级 | 买入 → 持有 |
| 05/17/2022 | 334.78% | 坎托·菲茨杰拉德 | 27 美元 → 5 美元 | 维护 | 超重 |
| 05/04/2022 | — | Cowen & Co. | 降级 | 跑赢大盘 → 市场表现 | |
| 05/04/2022 | 73.91% | Evercore ISI 集团 | 40 美元 → 2 美元 | 降级 | 跑赢大盘 → 在线 |
| 04/18/2022 | 3117.39% | HC Wainwright & Co. | 43 美元 → 37 美元 | 维护 | 买 |
| 03/21/2022 | 3639.13% | HC Wainwright & Co. | 40 美元 → 43 美元 | 维护 | 买 |
| 10/01/2021 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 2021 年 1 月 22 日 | 3378.26% | HC Wainwright & Co. | 33 美元 → 40 美元 | 维护 | 买 |
| 2020 年 12 月 16 日 | 3986.96% | 贝伦贝格 | → 47 美元 | 启动覆盖范围开启 | → 购买 |
| 11/23/2020 | 2769.57% | HC Wainwright & Co. | 28 美元 → 33 美元 | 维护 | 买 |
| 09/29/2020 | 5986.96% | Evercore ISI 集团 | → 70 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 05/11/2020 | 2334.78% | HC Wainwright & Co. | 25 美元 → 28 美元 | 重申 | → 购买 |
| 03/17/2020 | 1726.09% | Stifel | 22 美元 → 21 美元 | 维护 | 买 |
| 11/05/2019 | 2943.48% | HC Wainwright & Co. | 28 美元 → 35 美元 | 维护 | 买 |
| 09/09/2019 | — | 詹尼蒙哥马利斯科特 | 启动覆盖范围开启 | → 购买 | |
| 09/04/2019 | 2334.78% | HC Wainwright & Co. | → 28 美元 | 假设 | → 购买 |
What is the target price for Spero Therapeutics (SPRO)?
Spero Therapeutics（SPRO）的目标价格是多少？
The latest price target for Spero Therapeutics (NASDAQ: SPRO) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $7.00 expecting SPRO to rise to within 12 months (a possible 508.70% upside). 6 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了Spero Therapeutics（纳斯达克股票代码：SPRO）的最新目标股价。该分析公司将目标股价定为7.00美元，预计SPRO将在12个月内升至12个月内（可能上涨508.70％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Spero Therapeutics (SPRO)?
分析师对Spero Therapeutics（SPRO）的最新评级是多少？
The latest analyst rating for Spero Therapeutics (NASDAQ: SPRO) was provided by HC Wainwright & Co., and Spero Therapeutics reiterated their buy rating.
Spero Therapeutics（纳斯达克股票代码：SPRO）的最新分析师评级由HC Wainwright & Co. 提供，Spero Therapeutics重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Spero Therapeutics (SPRO)?
Spero Therapeutics（SPRO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spero Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Spero Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Spero Therapeutics的最新评级是在2023年11月14日公布的，因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Spero Therapeutics (SPRO) correct?
分析师对 Spero Therapeutics (SPRO) 的评级正确吗？
While ratings are subjective and will change, the latest Spero Therapeutics (SPRO) rating was a reiterated with a price target of $0.00 to $7.00. The current price Spero Therapeutics (SPRO) is trading at is $1.15, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但Spero Therapeutics（SPRO）的最新评级得到了重申，目标股价为0.00美元至7.00美元。Spero Therapeutics（SPRO）目前的交易价格为1.15美元，在分析师的预测区间内。